Action against misleading ads On 10 March, 2026, the DCGI issued a comprehensive advisory to all drug manufacturers ordering them to stop misleading advertisements and any promotion that could encourage people to use GLP-1 drugs without prescription
Nuestra cartera de diversas formulaciones de caractersticas avanzadas tales como las tabletas efervescentes, gummies, blando y duro cpsulas, tabletas masticables, oral, las gotas de lquidos, polvos, y el pet suplementos
Clinical data shows average weight reductions of 510% at 12 weeks when combined with lifestyle modification
Clinical studies show that people taking tirzepatide continuously experienced 20% weight loss or more after 72 weeks of continuous treatment
2), NAD + in erythrocytes of the eight study subjects did not correlate with age (Fig
Klarna, Affirm and Afterpay available for Quarterly Plans